The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 333:1570-1572 December 7, 1995 Number 23
NextNext

The Prevention of Coronary Heart Disease in Women

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: Lipid-lowering drugs are generally expensive and frequently have bothersome side effects. Although primary-prevention trials have shown that lipid-lowering therapy can reduce the incidence of coronary heart disease in middle-aged men, meta-analysis of these trials has shown no effect of this type of therapy on overall survival.1 Concern about serious adverse effects of lipid-lowering drugs has prompted some to urge caution in their use in healthy, asymptomatic people.2

Although the Journal's recent review of primary prevention of coronary heart disease in women (June 29 issue)3 does not directly advocate the use of lipid-lowering drugs in women, we . . . [Full Text of this Article]

References




HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.